ChestEye
AI-powered detection for 75 chest X-ray findings with preliminary reporting
Software · Cloud SaaSCompany source
Company profile
About Oxipit
Oxipit is a leader in AI-driven medical imaging, founded in 2017 by experts in medicine and data science. Since 2026, the company has been part of Sectra, one of the world's leading providers of enterprise imaging and healthcare IT. Oxipit develops clinically validated radiology AI solutions that help healthcare providers improve efficiency, support diagnostic workflows, and focus on patient care. The company's flagship innovation, ChestLink, launched in April 2022 as the world's first CE Class IIb-certified autonomous AI application for healthy chest X-ray reporting, capable of identifying normal studies with 99.9% sensitivity and automating up to 40% of cases. What started with chest X-ray AI has expanded into three comprehensive suites: the CXR Suite, CT Suite, and MSK Suite, covering chest X-ray, chest CT, and musculoskeletal imaging. In 2019, ChestEye received CE certification for generating preliminary reports for 75 chest X-ray findings. Each suite is designed to streamline radiology workflows, reduce oversights, and support confident decision-making. Oxipit's solutions integrate seamlessly into existing PACS and healthcare IT systems through partnerships with leading AI marketplaces and imaging platform providers. Trusted by healthcare providers worldwide, from major hospitals to remote clinics, Oxipit continues to advance AI-powered diagnostics, strengthening Sectra's vision for integrated and AI-enabled diagnostic workflows.
Company description Oxipit official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Oxipit?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Chest CT findings
- Chest X-ray pathologies (75 findings)
- Musculoskeletal conditions
- Tuberculosis
Who it serves
- Diagnostic Centers
- Health Systems
- Hospitals
- Radiology Practices
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: Blackford platform, CARPL platform, deepcOS platform, Newton's Tree platform, PACS systems.
Geographic context
MarketsAfrica · Austria · Cyprus · Europe · Germany · Global · Nigeria
Company sourceOfficial website
Company milestones
Platform expansion
Acquired by Sectra in March 2026. Launched CT Eye and MSK Eye in February 2026, expanding beyond chest X-ray. Selected by German Medical Institute and Diagnostikum Group (Austria) in 2025-2026. Demonstrated solutions at European Congress of Radiology (ECR) 2026.
Partnerships
Recorded partners
- Blackford
- CARPL
- deepc
- HealthCare Konnect
- Newton's Tree
- Sectra (parent company since 2026)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
ChestEye Quality
Real-time quality assurance for chest X-ray imaging
Software · Cloud SaaSCompany source
ChestLink
World's first autonomous AI for healthy chest X-ray reporting
Software · Cloud SaaSCompany source
CT Eye
AI solution for chest CT imaging workflows
Software · Cloud SaaSCompany source
MSK Eye
AI solution for musculoskeletal X-ray imaging
Software · Cloud SaaSCompany source
Oxipit CT Suite
Comprehensive AI suite for chest CT workflows
Platform · Cloud SaaSCompany source
Oxipit CXR Suite
Comprehensive AI suite for chest X-ray workflows
Platform · Cloud SaaSCompany source
Oxipit MSK Suite
Comprehensive AI suite for musculoskeletal imaging workflows
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Artificial intelligence-assisted double reading of chest radiographs to detect clinically relevant missed findings: a two-centre evaluation.European radiology · Sep 1, 2024
CATARACTS: Challenge on automatic tool annotation for cataRACT surgery.Medical image analysis · Feb 1, 2019
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
99.9% sensitivity
Identifying normal chest X-ray studies
Up to 40% automation
Percentage of chest X-ray cases automated and removed from worklist
75 pathologies detected
Number of chest X-ray findings detected by ChestEye
German Medical Institute
Selected Oxipit as chest X-ray AI partner following structured clinical evaluation of three leading vendors across 700+ real-world cases for pathology detection (CAD), smart triage, and semi-autonomous pre-populated reports
Chosen after rigorous evaluation focused on clinical reliability, workflow integration, reporting efficiency and practical usability
Healthcare institutions in Nigeria
Partnership with Healthcare Konnect to bring ChestEye AI imaging suite to healthcare institutions in Nigeria for detection of 75 pathologies including tuberculosis
Bringing AI diagnostic capabilities to one of the largest markets in Africa
Diagnostikum Group
Selected Oxipit CXR Suite to enhance chest X-ray workflows across its network after rigorous multi-vendor evaluation
Implementation across Austria's foremost diagnostic provider network
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from Oxipit
Recent articles published on Oxipit's official website.
Diagnostic confidence at speed: how FIDI uses Oxipit AI through CARPL in emergency care
Read on OxipitDiagnostikum Group selects Oxipit CXR Suite after rigorous multi-vendor evaluation
Read on OxipitUKIO 2025 reflections: autonomous AI is ready. The question is — are we ready to use it?
Read on OxipitOxipit welcomes new strategic advisor
Read on OxipitOxipit enters agreement to be acquired by Sectra to scale autonomous AI in radiology
Read on Oxipit07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.